Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.39 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17571008 | 1.00 | PTPRC (0.39) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL17570949 | 1.00 | PTPRC (0.39) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL31011009 | 0.98 | PTPRC (0.40) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL18411642 | 0.96 | REN (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL22005968 | 0.96 | REN (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL21990730 | 0.96 | REN (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL17570948 | 0.91 | CASP1 (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL19656354 | 0.91 | CASP1 (0.38) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL18411799 | 0.90 | RECQL (0.40) | PTPRCPTPN13RENHDAC8L3MBTL1 | |
| SCHEMBL18913933 | 0.90 | RECQL (0.40) | PTPRCPTPN13RENHDAC8L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981688-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4361128-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3880681-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230045079-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230045079-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11396519-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11396519-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210122768-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-04-29 | — | — | US | disclosed |
| US-20210122768-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-04-29 | — | — | US | disclosed |
| US-10851117-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851117-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200172555-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172555-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-06-04 | — | — | US | disclosed |
| WO-2020102051-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981688-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | PTPRC 4416/4885PTPN13 4698/4885REN 4348/4885 |
| US-10851117-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | PTPRC 4416/4885PTPN13 4698/4885REN 4348/4885 |
| US-20230045079-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | PTPRC 4416/4885PTPN13 4698/4885REN 4348/4885 |
| US-20200172555-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | PTPRC 4416/4885PTPN13 4698/4885REN 4348/4885 |
| US-20210122768-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | PTPRC 4416/4885PTPN13 4698/4885REN 4348/4885 |
| US-11396519-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | PTPRC 4416/4885PTPN13 4698/4885REN 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.